Tom Spurgeon10.11.11
Catalent Pharma Solutions’ $410 million purchase of Aptuit LLC’s clinical trial supply business in late August was the key event in a recent spate of maneuvers by, and continued development from, contract service providers in this important sector. Contract Pharma talked to several companies working in the outsourcing of clinical trial supplies and services to take the temperature of the business as it’s currently constituted, and to unearth developing trends for the immediate and long term.
With Catalent claiming to have become the number two provider of clinical trial solutions worldwide after its purchase of Aptuit’s resources and personnel, the question for a lot of industry observers becomes, will the move trigger a wave of consolidation? Several respondents acknowledged this as a definite possibility. An adamant few, however, saw the move in terms of the market’s overall development: a continuation of existing trends rather than a trigger for new ones.
“I think there is definitely saturation in the marketplace, as we are finding that existing commercially focused CMOs are now trending to offer clinical suppli
With Catalent claiming to have become the number two provider of clinical trial solutions worldwide after its purchase of Aptuit’s resources and personnel, the question for a lot of industry observers becomes, will the move trigger a wave of consolidation? Several respondents acknowledged this as a definite possibility. An adamant few, however, saw the move in terms of the market’s overall development: a continuation of existing trends rather than a trigger for new ones.
“I think there is definitely saturation in the marketplace, as we are finding that existing commercially focused CMOs are now trending to offer clinical suppli
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
